{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit not calculated due to insufficient number of events per Kaplan-Meier product-limit estimates.","groupId":"OG000","lowerLimit":"18.2","upperLimit":"NA","value":"NA"},{"comment":"Median and upper limit not calculated due to insufficient number of events per Kaplan-Meier product-limit estimates.","groupId":"OG001","lowerLimit":"42.8","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from randomization to death due to any cause. Estimates of time to event are from Kaplan-Meier product-limit estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to time of death due to any cause (Up to 36 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}